Vor Biopharma Inc. filed a Current Report on Form 8-K on November 12, 2026, disclosing that on November 11, 2026, the company entered into an amended and restated license agreement with RemeGen Co., Ltd. that expands the existing telitacicept license to include a second pipeline asset, RC298, in exchange for a $10 million upfront cash payment and a pre-funded warrant to purchase 2,300,000 shares of common stock.

Key Highlights

  • Expanded license: The amended agreement adds RemeGen's novel dual-target fusion protein RC298 and certain related compounds to the existing license covering telitacicept, covering all territories outside of Greater China.
  • Upfront consideration: Vor Biopharma will pay RemeGen $10 million in cash and issue a pre-funded warrant to purchase 2,300,000 shares of common stock at an exercise price of $0.0001 per share.
  • Milestone exposure: RemeGen is eligible to receive up to $330 million in regulatory milestones for the Initial Licensed Products, up to $300 million in development and commercial milestones for the Additional Licensed Products, and up to $3.775 billion in sales milestones across all Licensed Products.
  • Royalties: RemeGen is entitled to tiered royalties on net sales ranging from high single digit to mid-teen percentages, subject to customary reductions, according to the filing.
  • Beneficial ownership cap: Exercise of the warrant is subject to a 9.99% beneficial ownership limitation, with a permitted increase to a percentage not exceeding 19.99% effective after 61 days' notice.
  • Registration obligation: The company is required to file a Form S-3 registration statement covering the warrant shares within 30 days of the Registration Rights Agreement date, and to use reasonable best efforts to have it declared effective within 75 days of initial filing.

Vor Biopharma and RemeGen Amend License to Include RC298, Closing Warrant Issuance on November 11, 2026

According to the filing, Vor Biopharma (NASDAQ:VOR) originally entered into a license agreement with RemeGen Co., Ltd. on June 25, 2025, granting it exclusive rights to develop and commercialize telitacicept outside of Greater China. The November 11, 2026 amended and restated agreement expands that arrangement by adding RC298, described in the filing as RemeGen's "proprietary novel dual-target fusion protein product," along with certain related compounds. The company received an exclusive license, even as to RemeGen, under RemeGen's patents and know-how to exploit, develop, and commercialize the Licensed Products in all territories other than Greater China, with the right to grant sublicenses.

As partial consideration for the Additional Licensed Products, the company agreed to issue to RemeGen a pre-funded warrant to purchase 2,300,000 shares of common stock at $0.0001 per share via a Securities Purchase Agreement, the closing of which also occurred on November 11, 2026. The holder may elect cashless exercise. If a registration statement registering the issuance of Warrant Shares is not effective at the time of exercise, the filing states the warrant may be exercised only on a cashless basis. Neither the warrant nor the warrant shares have been registered under the Securities Act of 1933, as amended, according to the filing.

The filing also discloses that if the company enters into a sublicense or divests rights to the Licensed Products prior to a specified development event, and other than in connection with a change of control, RemeGen is entitled to receive a single digit percentage of certain net proceeds from such transaction. The company is responsible for all development, regulatory, and commercialization activities and costs in the licensed territory, including clinical trials and regulatory submissions. The Amended and Restated License Agreement may be terminated by either party for material breach, insolvency, by the company for convenience with advance notice, or by RemeGen if the company challenges the validity of licensed patents.

What Was Disclosed

Vor Biopharma disclosed the execution of an amended and restated license agreement with RemeGen adding RC298 to its licensed portfolio, a $10 million upfront cash payment, issuance of a pre-funded warrant for 2,300,000 shares, and associated securities purchase and registration rights agreements, all dated November 11, 2026.